Table 2. Comparison of concordance in published liquid biopsy studies.
| Zill et al. 2015 [11] (N = 26) |
Lanman et al. 2015 [10] (N = 165) |
Bettegowda et al. 2014 [23] (N = 206) |
|
|---|---|---|---|
| Patient Characteristics | |||
| Cancer Type | 18 PDA 8 Biliary |
57 Colorectal 22 Other GI 86 Other |
206 Colorectal |
| Stage | 3 Stage III 23 Stage IV |
40 Stage III 120 Stage IV 5 Unknown |
206 Stage IV |
| Tumor Biopsy Site | 11 Primary 15 Metastasis |
Unspecified | Unspecified |
| Info | |||
| Assay | cfDNA | cfDNA | cfDNA |
| Commercial Lab | Guardant Health | Guardant Health | PGDx |
| Liquid-Tumor Comparison | |||
| Overall Sensitivity | 92.3% | 85% | Unspecified |
| KRAS Sensitivity | 100% | 88% | 87.2% |